Databricks, Clay, and other companies featured are identified as leaders in the fastest-growing AI segment, suggesting Battery Ventures' interest in this category.

Battery Ventures believes AI company building, scaling, and selling requires specific expertise and convening of fast-growing AI companies with enterprises.

The concept of 'Intentional Breakage' suggests Battery Ventures believes companies must disrupt their own business models proactively in response to AI, rather than wait for disruption.

Battery Ventures is focused on how AI is fundamentally changing business models and revenue structures, suggesting they view AI-driven transformation as a key investment thesis.

Traditional SaaS-era playbook for building durable companies is obsolete; AI era represents rare but high-stakes moment requiring fundamentally different approaches to GTM and operations.

Clay scaled from $1M to $100M ARR in two years through early principled GTM decisions including targeting go-to-market engineers and implementing usage-based pricing.

AI-era hiring prioritizes builders with agency and drive over pedigree and operational experience; companies should hire for slope, curiosity, and differentiation rather than proven track record.

Successful AI-era founders make deliberate early bets on market direction and align organization around conviction before market validation, rather than reacting to market signals.

Enterprise buyers now require proven ROI and architecture flexibility rather than pilot programs; founders must lead with business problems and adapt to enterprise data/security constraints.

AI-native companies should organize GTM around customer journey rather than functional silos, with AI democratizing access to data across teams rather than following traditional SaaS playbooks.

Clinical trial patient screening is the primary bottleneck in bringing oncology drugs to market, accounting for up to 25% of coordinator time at oncology sites.

Oncology trials represent 41% of all clinical trials globally with 58% growth over past decade, driven by AI-assisted drug discovery and WHO projections of 77% cancer case increase by 2050.

LLM-powered AI is now enabling previously unsolvable clinical workflows, specifically reasoning over long multimodal medical records where keyword search fails.

Battery Ventures led Triomics' latest financing round. Triomics is an AI infrastructure company solving clinical trial patient matching in oncology with 95% accuracy and customers including MSK, MD Anderson, and Yale Cancer Center.

AuditBoard achieved $200 million ARR by early 2024 and was acquired by Hg for more than $3 billion, representing a successful SaaS scale-up in risk and compliance.

Market opportunity exists for 'connected risk' platforms that integrate controls across operational, financial, and supply chain risk silos rather than treating them separately.

CFO suite software, including audit and risk-management tools, represents an under-invested area of enterprise SaaS with significant innovation potential.

Battery led AuditBoard's Series B financing round in 2018, recognizing an under-invested CFO suite market opportunity with purpose-built tools for auditors and connected risk management.

Winning fintech AI companies will lead with proof-of-concept results and case studies rather than promises, and solve data integration at the product level rather than requiring manual deployment.

Specific fintech companies targeting CFO workflows identified across categories: Ramp, Brex, Lev Path, Zip (AP); Cube, Summation, Pigment (FP&A); Maxio, Monk, Stuut (AR); and multi-purpose platforms like Campfire, Rillet, DualEntry.